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perceptions
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Abstract
Background: Adult Attention-Deficit/Hyperactivity Disorder (ADHD) is associated with high rates of comorbid
substance use disorders, and cigarette smoking has a particularly high prevalence in this population. However,
there is an ongoing debate as to whether this tobacco use is an attempt at “self-medication” or due to behavioral
disinhibition. There is a surprising lack of qualitative studies that investigate the subjective perceptions of adults
with ADHD regarding cigarette smoking. The present study was designed to fill this gap in the literature.
Methods: We recruited twelve adult patients with ADHD and comorbid tobacco use from our ADHD consultation
service, an outpatient facility of the Zurich University Psychiatric Hospital. Subjects were interviewed using
qualitative methodology, and Mayring's qualitative content analysis was used to evaluate findings.
Results: We identified two explanatory models linking ADHD and tobacco use: smoking as an attempt at self-medication
and “smoking as a social behavior”. On one hand, subjects considered tobacco a therapeutic aid, reporting positive
effects on “inner tension” and cognitive function, and noted possible antidepressant properties as well. On the other
hand, subjects considered smoking to enhance social functioning and to have a positive impact on interpersonal
relationships. The majority believed that stimulant medications offered only a transient decrease in patterns of tobacco
use because their ability to reduce nicotine cravings wore off quickly. Others believed that stimulants had no effect or
even reinforced cigarette use.
Conclusions: Participants had different views about the link between cigarette smoking and ADHD. While the majority
thought of nicotine as a sort of therapy, viewing smoking as a way to self-medicate symptoms of ADHD, motivations for
nicotine use were also related to self-image, desire to belong to a peer-group, and a drive to undermine perceived social
norms. Ultimately, these findings can be used by clinicians to improve treatment alliance and collaboration.
Keywords: Adult ADHD, Nicotine use, Explanatory models, Reasons for use, Qualitative
Background
It is well established that Attention-Deficit/Hyperactivity
Disorder (ADHD), a highly prevalent neuropsychiatric
disorder that begins during childhood, largely persists into
adolescence and adulthood [1-3]. ADHD is characterized
by a diverse range of psychosocial impairments [4] and is
highly comorbid with a wide range of other mental disorders.
The most prevalent of these are mood disorders, anxiety
disorders, impulse control disorders, and substance-use
disorders (SUD) [5-7]. In adults with persistent ADHD, the
prevalence of a comorbid SUD has been estimated at 47%
or even higher in some series [8-10]. Furthermore, patients
with ADHD show significantly higher rates of cigarette
smoking than do members of the general population
(35 - 55%) [11-13], as compared to 19% - 40% [14-16].
A larger epidemiological study was conducted to obtain
knowledge about the association between ADHD and
tobacco consumption in a Swiss sample of adult ADHD
patients; previously, research on this subject had stemmed
primarily from North America. Our findings were based
upon complete data from 100 adult ADHD patients. In
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this study, which is only published in German, we
reported a significantly elevated rate of current smokers in
our sample (55%), as compared to 31% in the general
Swiss population [13].
There is ongoing debate in the research community
whether this ADHD-associated tobacco use is an
attempt at “self-medication” (i.e., to attenuate symptoms
of inattentiveness and improve executive function and
cognitive performance), if it is simply a consequence of
an underlying deficit in the ability to inhibit maladaptive
impulses [17], or if the elevated risk for SUD (in general)
is a “discrete dimension” [18] of inattention [19] or
impulsivity [20]. Moreover, there are contradicting reports
on the effects of stimulant medications on smoking
behavior among adults with ADHD. Some reports
point toward no effect [21], or a very modest decrease in
tobacco consumption [22], while other authors associate
stimulant treatment with increased tobacco use and
nicotine craving in healthy volunteers [23], as well as
in affected individuals [24].
The findings of some studies support the self-medication
argument that nicotine improves self-rated vigor and
concentration as well as performance on objective tasks,
including chronometric measures of attention and timing
accuracy [25-27]. Furthermore, deficits in sustained
attention are among the most consistent findings in
studies of the cognitive deficits associated with ADHD
[28]; considering that nicotine has positive effects on
sustained attention, some authors have argued that
patients with ADHD use cigarettes to ameliorate a
deficit in this function [29]. Aside from nicotine’s
generally positive effect on cognitive function [30],
smoking has also been linked with self-medication of
emotional dysfunction in ADHD [31].
As to the behavioral disinhibition argument, some
investigators report that ADHD is a specific, independent
risk factor for tobacco use in the clinical samples they stud-
ied, after controlling for comorbid conduct disorder (CD)
[10,32]. However, other authors suggest that orbitofrontal
dysfunction and disinhibition are associated with antisocial
behavior and related personality traits, and therefore with
tobacco use [33,34]. Sousa et al. investigated a sample of
422 patients with adult ADHD and concluded that smoking
initiation among patients with ADHD is associated with
behavioral disinhibition beyond self-medication [17]. They
also found that smoking on the part of these subjects was
consistently linked to externalizing comorbid disorders
such as CD and antisocial personality disorder.
In addition, Ivanov et al. suggest that the observed
relationships among ADHD, CD, and SUD might result
from the impulsivity present within each disorder, and
concluded that underlying deficits in inhibitory control
might play a central role in many of the behaviors
associated with a high risk for SUD [18].
Supporting evidence for the self-medication and the
disinhibition arguments has primarily been generated
by means of quantitative research methods, such as
epidemiological studies [11,32], systematic reviews
[10], or clinical pharmacological trials [27,35]. Since
studies of patients’ subjective perceptions have made
valuable contributions to our understanding of other
clinical issues, such as their perspectives on medication
adherence and the causes of mental illness [36-38], the
lack of qualitative research on the link between adult
ADHD and cigarette smoking is surprising.
Smokers in the general population attribute their
smoking to subjectively beneficial psychological and
physiological effects, and they smoke more when they
are in stressful life situations, are angry and anxious, or
are depressed [39-41]. Furthermore, it is likely that
tobacco use is heavily influenced by cultural factors such
as race, acculturation, or socioeconomic status, beyond
the pharmacology of nicotine, and frequently occurs
as a consequence of a cluster of social behaviors that
facilitate social interaction [42]. For example a recent
study among a large social network of 12 067 people
found that “smoking behavior spreads through close
and distant social ties” [43]. It has also been widely
reported that peer influences on smoking behavior
are stronger among white adolescents than among
other subgroups such as African American, Asian or
Hispanic adolescents [44].
The current study explored how patients with adult
ADHD, who currently smoked, viewed the relationship
(− or link) between nicotine use and ADHD, using an
inductive qualitative approach that made no initial
assumptions about the relationship between ADHD
and nicotine use. Thus, this study was not designed to test
whether the above-described hypotheses regarding this
link, identified using quantitate research methods, are
consistent, but to “allow the research findings to
emerge from the frequent, dominant, or significant
themes inherent in raw data” [45]. We further explored
how patients perceived the influence of prescription
medications (both stimulants and non-stimulants) on
patterns of tobacco use.
There is ample reason to believe that such qualitative
investigations would be fruitful, especially in an effort
to undertake a “collaborative or relationship centered
treatment approach”, that allows for treatment providers
and patients to allow a “mutual exchange of views” in
an effort to solve problems in the patient’s best inter-
est [46,47].
Methods
Sampling and recruitment
We recruited 12 participants from a larger epidemiological
study of 134 adult patients with ADHD who had presented
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to the ADHD consultation service at the Centre for
Addiction Disorders, an outpatient facility of the Zurich
University Hospital, Switzerland [13,48].
In order to more thoroughly examine patients’ beliefs
and perceptions about links between ADHD and cigarette
smoking, we conducted a series of qualitative interviews
using a purposeful sampling plan. All participants
included in this study were adults with a diagnosis of
ADHD and a current use of tobacco. They were also at
least 18 years old and willing to give written informed
consent for the study and the digitally recorded interviews.
The sample was selected to provide diversity in relation
to: (1) level of nicotine dependence (very low to very high);
(2) clinical experience (previous in- and outpatient
treatment episodes), including comorbidity (ICD-10 F3,
F4 + F6); (3) gender (m/f ) and age (25–52); (4) marital
status (married, single, divorced); and (5) social class
(professional, skilled, unskilled, unemployed, recipient
of welfare or disability compensation). We also sampled
for participants who had participated in a smoking
cessation program (8) and for those who had not (4).
Fifty-five participants of the larger epidemiological
study qualified for inclusion. We were able to reach
48 of them and 12 agreed to participate.
Obstacles to study participation were rarely addressed
by potential participants. Most often participants reported
of a lack of time. In three cases, potential participants
agreed to be interviewed, but failed to keep their
appointment and could not be reached afterwards.
Other potential barriers could have included a lack of
compensation [49], a lack of interest in the specific
research topic or a perceived lack of anonymity because of
digital recording.
Assessment of ADHD symptomatology
The diagnosis of ADHD was evaluated based on Utah
criteria for diagnostic assessment, using the Wender
Reimherr Interview (WRI) [50], translated into and
validated for the German language by Rösler et al. and
Retz-Junginger et al. [51-53]. Patients also received
German versions of the Symptom Check List 90-Revised
(SCL-90-R) [54], the Wender Utah Rating Scale (WURS-k)
[52], and the Attention Deficit-/Hyperactivity Self-Report
Scale (ADHS-SB) [55].
Assessment of tobacco and other substance use
For each participant, the clinic’s complete chart was
available, including biographical and psychiatric his-
tory, diagnoses according to the 10th revision of the
International Classification of Diseases (ICD-10), and
a detailed history of recent and lifetime substance-use
patterns. Nicotine dependence among participants was
further assessed with the 6-item Fagerstrom Test for
Nicotine Dependence (FTND) [56].
Qualitative interview
Participants were contacted by telephone to discuss the
purpose of the study, obtain their informed consent, and
arrange an initial interview. To allow for an atmosphere
in which the participants felt free to fully express
themselves, the interviews were then conducted at a
location chosen by the participant [57].
We conducted single, semi-structured, in-depth inter-
views that lasted from 20–40 minutes, with an average
duration of 30 minutes. Interviews began with narrative
opening questions. A topic guide provided a flexible inter-
view framework to explore beliefs that were not spontan-
eously covered in participants’ initial narrative. The guide
addressed tobacco use patterns, reasons for tobacco use,
influence of prescribed drugs on tobacco use, and the role
and use of additional psychotropic substances. In addition,
we allowed themes and motives identified during the
first interviews of this qualitative study to be explored
in the ones that followed, combining the principles of
maximum variation and complexity reduction in order to
simultaneously widen the scope of results and examine
previous assumptions [58].
All interviews were conducted by the same researcher
in Swiss German (an Alemannic dialect spoken in
the “German-speaking” parts of Switzerland). They
were digitally recorded and transcribed verbatim into
Standard-German, since Swiss German is not a “written
language” by AF. Transcripts were compared with
recordings by the research team and validated with pa-
tients if necessary. Content analysis was carried out in
German. Interpretation of findings and translation of se-
lected quotes from German to English was carried out by
ML. Translation errors (grammatical) were discussed be-
tween ML and CF, and corrected by CF. Subjects did not
receive compensation for their participation.
All researchers had received training either as psycholo-
gists (AF) or as psychiatrists (ML, CF, AB, DE) and had pre-
vious research experience with qualitative methods.
Analysis
Mayring's qualitative content analysis approach was used
to evaluate findings. This framework constitutes a
controlled approach for empirical and methodological
qualitative analysis of texts within their context of
communication, following content analytical rules and
step-by-step models, without rash quantification [59]. In
other words, we allowed the data to "speak for themselves,"
as opposed to approaching it with existing presumptions.
Interview data were coded using an inductive qualitative
procedure [60]. The resulting categories were discussed
by the research team to validate ratings and achieve
consensus. AF applied the final code, and consistency
was confirmed through blind dual coding of transcripts
with ML. If there was disagreement, researchers met to
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discuss and reconcile the coding. This did not become ne-
cessary until the late stages of revising the submitted manu-
script and can be traced using the pre-publication history
of this article on biomedcentral.com. Participant recruit-
ment continued until we reached saturation of the data—i.
e., there were no new themes emerging and we had tested
all the categories for disconfirming variations. MAXqda
software was used for text management and interpretation
[61]. The study was authorized by the ethics committee of
the canton of Zurich and all participants provided their
written informed consent for it and the recorded
interviews.
The topic guide is presented in Table 1.
Results
Participant characteristics, diagnosis, and tobacco con-
sumption patterns are described in Table 2.
Of the 12 participants, seven were female and five
were male. Their average age was 40, and they ranged
from 25–53. At the time of the interview, all participants
were currently smoking cigarettes, but their patterns of
smoking varied greatly (from a minimum of 3–5 a week
to a maximum of 35 a day), as did the severity of their
nicotine dependence, according to the FTND (from very
low to very high).
Ten participants had the combined type of ADHD,
one had the predominantly inattentive type, and one had
the predominantly hyperactive-impulsive type. All but
two had another comorbid mental disorder. The most
common comorbidities were SUD (other than nicotine
dependence) and affective disorders. Six participants (50%)
were employed, two (16%) were students, and four (33%)
were unemployed or had an uncertain employment status.
In our analysis of the interview data, we identified
two main themes linking ADHD and tobacco use:
smoking as an attempt at self-medication, and smoking as
sensationalism, the search for a positive self-image and
peer-group-mediated behavior. Examples of these themes
follow, but it bears noting that there was significant
overlap among themes: some participants identified
more than one specific link between ADHD and
smoking and had adopted a multifaceted explanatory
model to describe the relationship. Following the descrip-
tion of those themes, we also describe participants’ beliefs
about the influence of prescription drugs and about their
experiences with other psychotropic substances.
Overall beliefs about the link between ADHD and
tobacco use
The majority of participants readily acknowledged that
cigarette smoking had psychological and physiological
effects on them. Nine study subjects described a link
between ADHD and tobacco use, but one participant
reported that he had not thought about a connection:
“I don’t know, and I don’t want to lie to you. Maybe, I
really don’t know. I cannot really judge it, because I
have always been the same, not one time with ADHD
and one time without it.”
Mrs. G.
Two participants did not address this subject in their
narratives. In order to avoid leading questions and to
preserve a non-judgmental stance, participants were not
pressed on this subject.
Theme I: Smoking as an attempt at self-medication
Most frequently, subjects acknowledged a link between
ADHD and tobacco use by giving reasons for smoking
cigarettes. Upon further exploration of the effects of
nicotine consumption, participants expressed very different
but generally positive views of those effects. Many
attributed their cigarette use to general feelings of stress
or being overwhelmed in different social contexts:
“…If I am getting out of some sort of stressful situation
and I get the feeling my brain ‘rotates,’ then I get the
feeling that I should go have a cigarette and then one
can see the world much clearer.”
Mr. K.
Other study subjects used cigarettes specifically to
reduce inner tension, to treat symptoms of restlessness,
and for relaxation purposes:
Table 1 Topic guide
Main questions “Can you tell me about your smoking?”
“Have you ever thought about your reasons for
smoking?”
“What is the purpose of smoking?”
“What are the effects if you smoke?”
“In your opinion, is there a relationship between
symptoms of ADHD and your personal patterns
of smoking?”
“If you used prescribed drugs for treatment of ADHD
(and/or other mental disorders) now or in the past, did
you notice a relationship between your use of these
drugs and your patterns of smoking?”
Additional
questions
“Did you (do you) notice any changes in (your
symptoms of ADHD) when you were smoking?”
“If you ever stopped smoking, did it have an effect on
you? What kind? For how long?”
Clarifying
questions
“Can you expand a little on this?”
“Can you tell me anything else?”
“Can you give me some examples?”
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Table 2 Participant characteristics, diagnosis, and tobacco consumption patterns (n = 12)
Namea SCb Age Cigarettes per day
at time of interview
Nicotine dependencec ADHD subtype ICD 10 comorbidity Use of other substances Current medication Previous phases of
nicotine abstinence
Mr. A. Yes 53 2 - 3 Very low Combined - - Stimulants 1 month (1993)
Mr. B. Yes 42 3 – 5/week Very low Inattentive F33.4 - Stimulants, antidepressants 7 years (starting 1996)
Mrs. C. Yes 25 20 Low Combined F12.24 Cannabis Stimulants, antidepressants 15 months (2002)
Mrs. D. Yes 46 20 High Combined F10.25 Alcohol Stimulants, antidepressants 6 months (1993
F11.20
F14.20
Mrs. E. Yes 27 20 Very high Combined - - Stimulants 4 – 5 years (2000)
Mrs. F. Yes 47 23 Very high Combined F43.21 - Stimulants, antidepressants 3 weeks (1994)
Mrs. G. Yes 42 30 Moderate Combined F43.21 - Antidepressants One year (2001)
Mrs. H. No 26 35 High Combined F43.21 - Stimulants, antidepressants 18 months (2003)
Mr. I. No 47 35 High Hyperactive/impulsive F12.24 Cannabis Stimulants 1 month (2003)
F60.2
Mrs. J. Yes 44 30 Very high Combined F11.202 Alcohol Stimulants 6 months (1984)
F41.2
Mr. K. No 46 33 Very high Combined F10.24 Alcohol Stimulants 1 month (1992)
F33.4
Mr. L. No 32 35 Very high Combined F10.25 Alcohol Stimulants None
F14.20
apseudonym.
bparticipated in smoking cessation treatment.
cnicotine dependence according to Fagerström.
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“It reduces tension, I even believe partially. It really
depends on the moment, but I would even say it
relaxes the muscles. Especially in those moments when
you have not smoked for a while and you absolutely
want to smoke, then you can notice this.”
Mrs. C.
Participants repeatedly commented on the positive
effects they perceived in relation to their ability to
concentrate, be attentive, and solve problems. Two
subjects also compared nicotine’s effects to those of
other substances.
“…and you know earlier I was using other [illegal]
drugs, and you know every time I had to do something,
on which I absolutely had to concentrate on,
something minor, then I would take heroin. Then I
could behave and concentrate. And it could have been
the most boring stuff in the world, for example. And
you know a cigarette has a very similar effect, like
alcohol, like some sort of sedative, which has the effect
on me that I can do something really boring,
something where I have to crunch numbers for hours
at a time, then [cigarettes] help me with that.”
Mrs. J.
One participant with major depressive disorder attributed
mood-stabilizing properties to nicotine:
“And you know, I am not accurately diagnosed with
ADHD. I am somewhere in between a depression and
ADHD, so this is an area where no one can say
exactly, and you know, I think that I come more
from the depressive side, in that sense it is a form
of self-medication. It is a surrogate to comfort yourself
and to retreat. Alone with one’s cigarette – it is almost
like you can solve all the problems of the world,
somehow, I think.”
Mr. B.
Another study subject associated a difficult upbringing,
including emotional neglect by his parents, with cigarette
smoking; he felt that it took the form of self-medication
for emotional dysfunction.
“I always had the feeling that I got too little emotional
warmth. Maybe it is because my mother was
overwhelmed, because I was an ADD child…but
something was missing all my life, despite the fact that
I have an intact marriage, children, family, and social
stability. I am compensating for something that is
missing. And if I can make that happen with 2–3
cigarettes, then I am very happy with that.”
Mr. A.
Theme II: Smoking as a social behavior
Subjects also frequently expressed the view that smoking
had positive effects on interpersonal relationships, a
valuable asset for socializing that could be used as a way
of connecting to others:
“…smoking gives me a feeling of belonging and
togetherness, something I can really enjoy, so I can lay
back and smoke one [cigarette]…I find it very pleasant
to be together with a group of people and everybody
says, let’s go, we will have a smoke, then I like it.”
Mrs. G.
Some participants had a completely different view,
primarily associating their tobacco use not with a search
for specific effects but with a desire to take risks, to try
something new with the appeal of the forbidden. We label
this subtheme “sensationalism.” One study subject believed
that patients suffering from ADHD are more likely to
use psychotropic substances in general. (Of note, this
subtheme has some overlap with views and perceptions
regarding the initiation of smoking and its effects on
interpersonal relationships.)
“Generally speaking, if I compare myself to others, I am
less fearful. My readiness to assume risk is just higher
compared to others, which is also a small part of the
reason I began to smoke. Although you know that
everything is harmful and so on, but the appeal of the
forbidden, to begin with, is something symptomatic for
individuals with ADHD, this wanting to know how it
really is, this experimenting and this behavior…”
Mr. B.
This subtheme is further illustrated by two female
participants, who described themselves as “rebellious”
and “revolutionary,” and expressed a desire to subvert
perceived social norms. Furthermore, they associated
smoking with a positive self-image.
“…it might be connected to the fact that I always was
a bit of a misfit as child, and later more into
revolution and rebellion. And as a smoker you were
somehow always more on the unhealthy side, but this
was very clear to me, and for years I thought ‘I don’t
want to quit smoking, the earlier I die…’ and so on…
[started giggling], yes, and I think it has to do with the
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fact that the people who smoke are not the usual ones…
and I identified myself with that…and I never had a
self-perception as a non-smoker…that did not fit…”
Mrs. C.
Unlike the participants who were looking for a sense of
belonging, other study subjects who had initiated their
tobacco use in adolescence voiced explanations that empha-
sized their search for a self-image of “coolness” among a
group of peers, even if they found smoking repelling.
“It was a process. Initially I found it disgusting, but I
wanted to belong to that group of people… I really did
have the feeling then, with smoking, that I am one of
the more cool people with a more laid-back style.”
Mrs. G.
Influence of prescription drugs on tobacco use patterns
All participants had some experience with prescribed
psychotropic medications, mostly stimulants and antide-
pressants. We describe these findings separately but do
not label them as a theme, because they do not present
explanatory models linking ADHD and tobacco use.
Subjects generally believed that medications had affected
their tobacco use patterns, though the medications’
influences were experienced and expressed quite differ-
ently. Some participants reported that stimulant therapy
(e.g., methylphenidate) initially reduced their tobacco
use patterns:
“… in the very beginning, right when I started, I had
the feeling that it did [decrease the desire for smoking],
but this effect wore off quickly. Yes, the first day I had
like no desire. Maybe I should take more Ritalin
[methylphenidate].”
Mrs. D.
Other subjects believed methylphenidate increased
their craving for smoking cigarettes:
“… I actually had the feeling that I was smoking
more cigarettes when I started Ritalin. Although
I don’t know how closely this is connected, but
I did have the feeling that it is, because I felt
I received for a time too high of a dosage, and
then when I had little highs, I noticed I smoked
or drank more.”
Mrs. H.
A minority did not notice any difference:
“… No my smoking patterns did not change much
when I started Ritalin, I am like that, it is a habit,
it is not about the smoking really. It is more, I answer
the phone and I have a cigarette, or I sit in front of my
computer and then I have one in my hand, I am not
even smoking it, because I am typing. Then my
keyboard is full of ashes, and smoke is in my nose but
not because I am inhaling, but just because the
cigarette is around…”
Mrs. J.
One study subject experienced a medication with
stimulant-like properties as so calming that her desire
for cigarette smoking abated:
“…I have the impression that, since Dexamin
[dexamphetamine], calms me down, calms me down
very much. I have the feeling that smoking became less
important and played only a minor role, because for a
time I was not smoking excessively. Yes, because I had
the feeling that I was calm, that smoking was not that
important anymore. I was still smoking out of habit,
but it still had an influence. Since with Ritalin I was
partially still very nervous and then smoking was
there, this goes hand in hand…”
Mrs. E.
Another participant had this experience with the use
of an antidepressant:
“… Really, I did not notice an effect at all and I had
been trying with Dr. Eich [DE] for three years now.
And the first time that I had the feeling that
[medication] was useful was with Fluctine [fluoxetine],
that gave me more of a balance…until now I had to
say, it is not working for me, Concerta
[methylphenidate] did not at all…”
Mrs. G.
Discussion
In this qualitative study, nine out of twelve subjects clearly
identified perceived links between tobacco use and their
ADHD. One had not thought about a connection and two
participants did not address this topic in their narrative. In
addition, subjects described an influence of prescription
medications, as well as an effect of other psychotropic
substances on their thoughts and behaviors related to
tobacco use.
We identified two core beliefs linking ADHD and
cigarette smoking. The first theme, smoking as an
attempt at self-medication, was adopted by the majority of
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the participants as their preferred description of the link
between smoking and ADHD. Subjects generally had a
positive view of the effects of tobacco, describing a
range of beneficial uses: reducing tension, alleviating
restlessness, relaxing in general, improving attention,
regulating emotional distress, and relieving depressive
symptoms. Thus participants might use tobacco to try
to treat the symptoms and cognitive deficits arising
from adult ADHD [62,63]. These qualitative reports are in
accord with previous findings that nicotine may improve
clinical symptoms and cognitive function in adults with
ADHD [26,64]. Overall, our results provide further
support for the hypothesis that smoking is a form of
self-medication among adults with ADHD [65].
The second theme, smoking as a social behavior
demonstrated that smoking was considered by many
to enhance social functioning and to have a positive
impact on interpersonal relationships.
Furthermore, some participants primarily initiated
tobacco use not to attenuate symptoms of inattention or
hyperactivity but to live a more exciting lifestyle, to
undermine perceived social norms, to enhance their self-
image, and to gain access to a desired non-conformist
peer group. It is possible that the ADHD participants in
this study who favored this motive are more impulsive
and behaviorally disinhibited than others [17]; however,
none fulfilled ICD-10 criteria for a conduct disorder in
the past, or a current personality disorder. It must be
noted that subjects who identified this motive began
smoking against the backdrop of their overall subjective
experiences, cultural norms and institutions, gender
roles, and aesthetics, all of which are strong influences
on smoking behavior in general [42,66].
At first glance, the views of our study participants do not
differ greatly from explanations given by cigarette-smokers
without ADHD. For example, a recent qualitative study of
cigarette-smoking college students found that smoking
“served as an aid in alleviating anticipated stress”; “helped
clear the mind when shifting from one subject to another”;
“helped to refocus thoughts during a study session, facilitat-
ing greater concentration”; “served as a reward to celebrate
the completion of a study session or an examination”; and
helped to change the mindset when “transitioning from
studying to being social” [67]. However, it must be noted
that nicotine effects in adults with ADHD might exceed
those in healthy volunteers, because they improve the
attention of the former, as well as their clinical symptom-
atology [68]. Comparisons with healthy volunteers or the
general population might therefore be misleading.
Finally, findings on the influence of prescription drugs
on tobacco use patterns were heterogeneous. Given that
existing literature on the effects of stimulant medication
on smokers with ADHD presents conflicting conclusions,
we were intrigued to learn how subjects would describe
the influence of stimulant medication on their tobacco-
use patterns. However, only a few subjects made a clear
assertion. The majority believed that the effects of
stimulant therapy on nicotine craving wore off quickly,
resulting in only a transient decrease in smoking, or
that stimulants had no effect on cigarette use or even
reinforced it. This supports Hurt et al., Winhusen et al.,
and Rush et al. [21-23].
Furthermore, Vansickel et al. recently reported that
immediate-release methylphenidate used by smokers
with ADHD actually increased both the total number of
cigarettes smoked and their carbon monoxide levels [69].
Other investigators did not find significantly increased
daily smoking rates in adults with ADHD [22]. It has been
suggested that differences in formulation might explain
this discrepancy [22]. In our sample, we did not find evi-
dence for a link between smoking patterns and stimulant
formulations.
We acknowledge the limitations of this study. First, we
wished to obtain a comprehensive understanding of
participants’ views, so we conducted extensive interviews
with a small sample. Second, all study subjects were
recruited from the same outpatient treatment facility, so
it is unclear to what extent the present findings can
be generalized. Third, since a majority of potential
participants could not be interviewed for this study,
there may have been an additional self-selection or
non-response bias, further limiting generalizability. Fourth,
interviews were conducted by a clinical psychologist and
analyzed by a team of psychiatrists and psychologists
actively involved in multimodal treatment for patients with
ADHD, which may have influenced categorization.
The results we have presented should therefore be
verified by further studies with more diverse patient
groups. An initial step could be to recruit participants
from more diverse treatment modalities, younger age
group (e.g. adolescents 15 – 18 years) and with a
wider variety of comorbidities. Since the majority of
our participants belonged to the adult ADHD com-
bined subtype, further research could also focus on
the inattentive and hyperactive subtypes or presenta-
tions according to DSM-V. Finally, we did not include a
non-ADHD comparison group, which could significantly
enhance our understanding of the perceived differences in
nicotine effects between adults with ADHD and the
general population.
Conclusion
Adults with ADHD and comorbid tobacco use expressed
different views on the link between cigarette smoking and
their ADHD. While the majority believed that nicotine
has a positive effect and considered smoking an attempt
at self-medication of ADHD symptoms, nicotine use was
also linked to a desire for “sensationalism”: the search for
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a positive self-image, desire to belong to a peer-group, and
a wish to undermine perceived social norms. Uncertainty
and diverse opinions arose in relation to the effect of
stimulant medications on patterns of tobacco use. Some
subjects believed that stimulants were helpful for smoking
cessation but that their positive effects wore off quickly,
while others felt that stimulants either had no effect or
worsened smoking.
Taken together, our findings suggest that neither
the self-medication hypothesis nor the behavioral
disinhibition model alone completely explains the link
between ADHD and cigarette use. We found support
for the self-medication hypothesis, but social and
cultural factors were also highly influential. Studies of
other mental disorders have established that patients
prefer to draw on their own experiences, and that
treatment approaches that do not take patients’ subjective
perceptions into account are unlikely to increase
help-seeking behavior [70]. We therefore suggest that
clinicians who treat adult patients with ADHD and
comorbid tobacco make use of the findings reported
here to work for optimal treatment alliance and
collaboration [71-73].
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